impaired fat metabolism overweight
Conditions
Interventions
During the test day (each approximately 6h per test day), rectal infusion of a
200mL solution with a combination with sodium acetate 24mmol, sodium butyrate
8mmol and sodium propionate 8mmol, a combi
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Overweight/obese men (BMI>=25kg/m2
Exclusion criteria
Exclusion criteria: - Type 2 diabetes mellitus (defined as FPG >= 7.0 mmol/l) - Gastroenterological diseases or abdominal surgery - Cardiovascular diseases, cancer, liver or kidney malfunction, disease with a life expectancy shorter then 5 years - Abuse of products - Plans to lose weight or following of a hypocaloric diet - Regular supplementation of pre- or probiotic products, use of pre- or probiotics 3 months prior to the start of the study - Intensive exercise training more than three hours a week - Use of any medication that influences glucose or fat metabolism and inflammation (i.e. NSAIDs). - Regular use of laxative products - use of antibiotics 3 months prior to the start of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome parameters are fat oxidation and energy expenditure. The impact of site of administration of SCFA on fat oxidation and energy expenditure will be studied as well as the duration of effect. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Hormones that influence substrate and energy metabolism like Insulin, Glucagon, GLP-1, PYY, FIAF; - Circulating metabolites like Glucose, Free Fatty Acids, Triglycerides; - Inflammatory markers like TNF-a, IL-6, IL-1, Adipokines; - plasma SCFA content - Indirect markers of insulin sensitivity like circulating insulin concentrations; - Appetite (VAS-scoring system). | — |
Countries
Netherlands
Outcome results
None listed